



⑯ Europäisches Patentamt
European Patent Office
Office européen des brevets



⑮ Publication number:

0 280 571 B1

⑯

EUROPEAN PATENT SPECIFICATION

⑯ Date of publication of patent specification: 04.08.93 ⑯ Int. Cl. 5: A61K 9/22, A61K 9/26

⑯ Application number: 88301684.2

⑯ Date of filing: 26.02.88

⑯ Sustained release matrix formulations.

⑯ Priority: 27.02.87 US 19915

⑯ Date of publication of application:
31.08.88 Bulletin 88/35

⑯ Publication of the grant of the patent:
04.08.93 Bulletin 93/31

⑯ Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

⑯ References cited:

EP-A- 0 129 382

EP-A- 0 142 877

GB-A- 2 067 072

US-A- 4 520 009

CHEMICAL ABSTRACTS, vol. 99, 1983, page
342, no. 110763c, Columbus, Ohio, US; &
JP-A-58 92 615 (HIGASHIKAWA, TETSUO)
02-06-1983

⑯ Proprietor: ELI LILLY AND COMPANY
Lilly Corporate Center
Indianapolis Indiana 46285(US)

⑯ Inventor: Oren, Peter Lloyd
33 Apple Tree Circle
Noblesville Indiana 46060(US)
Inventor: Seldler, Werner Max Karl
1647 West 72nd Street
Indianapolis Indiana 46260(US)

⑯ Representative: Tapping, Kenneth George et
al
Erl Wood Manor
Windlesham Surrey, GU20 6PH (GB)

EP 0 280 571 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

This invention relates to sustained release pharmaceutical formulations, particularly those containing antimicrobial agents.

5 Ideally, a sustained release dosage form should deliver the medicament at a constant rate throughout the gastrointestinal tract. With many of the delivery systems currently available, this expectation may not be realized since many drugs which are weakly acidic or basic exhibit solubility which varies in relation to pH. A decline in solubility in response to pH fluctuations within the body may result in a decreased release rate if the formulation does not respond with an appropriate change in its permeability characteristics.

10 The use of hydrophilic matrices to provide sustained drug release is known. Christenson et al. in U.S. Patent 3,065,143 disclose the use of certain hydrophilic gums, including hydroxypropyl methylcelluloses, in the preparation of sustained release tablets. Hill in U.S. Patent 3,458,622 describes the preparation of sustained release tablets using a combination of povidone and carbopol. Chem Abs 99, 1983 no.110763c describes a sustained release matrix containing a hydrophilic polymer and an enteric polymer. EP-A-142877 15 describes a sustained release matrix having an inert and a hydrophilic substance. GB-A-2067072 describes tablets containing a release-controlling agent and an erosion-promoting agent. US-A-4520009 describes constant-release aspirin tablets containing cellulose acetate phthalate and a plasticiser. Wiess et al. in U.S. Patent No. 4,252,786 describe a controlled release tablet consisting of a core tablet which was identical to the tablet disclosed in Hill, that is, containing an active ingredient, povidone, and carbopol. A coating 20 consisting of a hydrophobic and a hydrophilic polymer was employed to prevent the initial burst of drug release encountered with this tablet. Schor et al. in U.S. Patent No. 4,389,393 describe sustained release therapeutic compositions based on high molecular weight hydroxypropyl methylcellulose.

Conventional hydrogels such as those based on high viscosity hydroxypropyl methylcelluloses are known to deliver medicaments at a constant rate independent of pH in relation to the hydration, gel 25 viscosity and relative permeability of the dosage form. This, however, does not ensure that a drug whose solubility varies significantly as a function of pH will be delivered at a constant rate throughout the gastrointestinal pH range. With these conventional hydrogel formulations, the rate of drug release will be directly related to the solubility of the drug. If the drug possesses greater solubility in gastric fluids as compared to intestinal fluids, a characteristic of many weakly basic active ingredients, one would expect the 30 release rate of the matrix to be faster in gastric fluids, than when the formulation makes the transition into the small intestine where the pH values are reported to be higher. For these formulations, if the dosage form is not retained for an adequate time period in the stomach, the decrease in drug release rate encountered in the intestine might result in incomplete bioavailability and greater variability from patient to patient.

35 Film coatings are known to have the ability to modify the release pattern of a drug once applied to pharmaceutical products. One type of film coating, known as an enteric coating, is used to prevent the release of drugs in, or protect drugs from, the effects of the gastric environment. Enteric coatings are used to delay the release of drugs which are inactivated by the stomach contents or which cause gastric irritation.

40 The matrix compositions of the present invention differ from existing formulations in that the present compositions have been designed to respond to increases in pH with a corresponding increase in the permeability of the dosage form. This allows the dosage form to release the active ingredient at an appropriate rate throughout the gastrointestinal tract.

45 This invention provides a matrix composition comprised of an active agent, a hydrophilic polymer, and an acrylic polymer which results in a dosage form which is responsive to physiological pH changes. More specifically, the present invention relates to a sustained release matrix formulation in tablet form comprising from about 0.1% by weight to about 90% by weight of an antimicrobial agent, from about 5% by weight to about 29% by weight of a hydrophilic polymer, and from about 0.5% by weight to about 25% by weight of an acrylic polymer, with the proviso that the total weight of the hydrophilic polymer and acrylic polymer is less than 30% by weight of the formulation. This formulation reacts to an increase in pH with a 50 corresponding increase in its permeability and rate of erosion. This results in an improved mechanism for the sustained delivery of a variety of compounds, especially those whose solubility declines as the pH is increased.

Amounts and percentages are described herein as weight units unless otherwise stated.

55 The present formulation is in the form of a matrix of the ingredients comprising the formulation. A matrix, as defined herein, means a well-mixed composite of ingredients fixed into shape by tabletting. This intimate admixture of ingredients provides sustained release of the active agent contained therein as the pH of the environment changes following administration to a patient in need of such prolonged payout.

The percent of the ingredients required in the formulation of the invention, namely the active ingredient, the hydrophilic polymer, and the acrylic polymer, is calculated on a dry weight basis without reference to any water present. Thus, these three components together constitute 100 percent of the formulation for the purposes of calculating individual percentages. If other ingredients are present, the sum of all of the components, with the exception of the film coating, if any, constitutes 100 percent of the formulation for purposes of calculating individual percentages. The antimicrobial agent will be present in a composition of the invention at a concentration in the range of about 0.1% by weight to about 90% by weight, more preferably at a concentration in the range of about 45% by weight to about 85% by weight. Typical medicaments which might benefit from this type of delivery system are antimicrobial agents such as 5 cephalixin, cefaclor, cefadroxil, cefuroxime, cefuroxime axetil, erythromycin, penicillin, 7-[D-(aminophenylacetyl)amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, also known as loracarbef, 10 7-[amino[3-[(methylsulfonyl)amino]phenyl]acetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, and 7-[D-[amino[3-[(ethylsulfonyl)amino]phenyl]acetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.

15 Examples of agents for which this invention is particularly suited are cephalixin and cefaclor. Both compounds are zwitterions, possessing both an acidic and a basic functional group. Both have greater solubility at the low pH values reported for gastric fluids (pH 1-3), than at the values normally reported for intestinal fluids (pH 5-7). When these compounds are placed into a conventional hydrogel, the release rate will be faster in simulated gastric fluids than when the formulation is exposed to simulated intestinal fluids.

20 The compositions of the present invention will also contain a hydrophilic polymer. Hydrophilic polymers will be present in the compositions of the invention at a concentration in the range of about 5% by weight to about 29% by weight, more preferably from about 5% by weight to about 20% by weight. Hydrophilic polymers suitable for use in this invention are either water soluble or water swellable, and include one or more natural or partially or totally synthetic anionic or nonionic hydrophilic gums, modified cellulosic 25 substances or proteinaceous substances such as acacia, gum tragacanth, locust bean gum, guar gum, karaya gum, agar, pectin, carrageen, soluble and insoluble alginates, methylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethylcellulose, sodium carboxymethylcellulose, carboxypropylmethylene, gelatin, casein, zein, bentonite, magnesium aluminum silicate and the like. Other hydrophilic polymers which could be employed include polysaccharides and modified starch derivatives such as 30 Amazio 721A (American Maize Products) and Pullulan (Hayashibara Biochemical Laboratories, Inc.).

Preferred hydrophilic polymers are the hydroxypropyl methylcelluloses manufactured by Dow Chemical and known as Methocel ethers. Preferred Methocel ethers include the Methocel E series gums (E 5, E 15, E 50, E4M, E10M and the like). The hydration rate of the Methocel E series gums is typically slower than the hydration rate of the Methocel K series gums. When the Methocel E series gums are used to prepare 35 hydrogel tablets, thinner gel layers will result. As a consequence, when these tablets are exposed to a media of higher pH, the tablets respond more quickly than when polymers which provide thick viscous gel layers are employed. Yet another preferred polymer is Pullulan, a water soluble polysaccharide which is derived from starch. Pullulan is similar to the Methocel E series gums in that hydrogel tablets containing Pullulan normally form thin gel layers. When employed in conventional hydrogel tablets, Pullulan has only 40 moderate ability to retard drug release.

The formulations of the invention will also contain an acrylic polymer. These polymers will be present in the compositions of the invention at a concentration in the range of about 0.5% by weight to about 25% by weight, more preferably at a concentration in the range of about 1.5% by weight to about 15% by weight. The pH at which these polymers begin to dissolve will be in the range of about 5.0 to about 7.4. The 45 polymers will be insoluble at a pH below about 5.0. Since these polymers are insoluble at the low pH values corresponding to gastric fluids, they aid in retarding drug release in these regions. When exposed to fluids of higher pH, similar to those found in the small intestine, these polymers will dissolve, and thereby increase the permeability and rate of erosion of tablets of the present invention. Examples of suitable polymers include acrylic resins such as Eudragit L, Eudragit S, Eudragit L-100-55- Rohm Pharma and 50 acrylic latex dispersions, for example, Eudragit L30D- Rohm Pharma. A preferred acrylic polymer is Eudragit L-100-55. This resin is available both as a fine powder or as an aqueous dispersion Eudragit L30D. This resin begins to dissolve above a pH of about 5.5, and for this reason aids in improving drug release over a major portion of the small intestine. The total concentration of the hydrophilic polymer and the acrylic polymer will be less than 30% by weight of the total formulation.

55 The present formulations may also contain a pharmaceutically acceptable binder at a concentration in the range of about 2.0% by weight to about 10.0% by weight, preferably from about 2.0% by weight to about 6.0% by weight. Pharmaceutically acceptable binders suitable for use in the present formulations are chosen from those routinely used by formulation chemists and include sucrose, lactose, gelatin, starch

paste, acacia, tragacanth, and other gums; cellulose derivatives such as methylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and ethylcellulose; microcrystalline cellulose; povidone; polyethylene glycols; corn syrup; and other binders known to those familiar with pharmaceutical formulations. Preferred binders are Pullulan and hydroxypropyl cellulose.

5 The present formulations may also contain from about 2.0% to about 25.0% by weight of a pharmaceutically acceptable excipient, preferably from about 5% to 20% by weight. These excipients may be water soluble and should be chemically inert to the other ingredients. Preferable excipients would include lactose and mannitol. Alternatively, a variety of other known excipients could be employed such as glucose, fructose, xylose, galactose, sucrose, maltose, xylitol, sorbitol, as well as other pharmaceutically acceptable 10 monosaccharides and disaccharides. Other suitable excipients would include inorganic compounds such as the chloride, sulfate and phosphate salts of potassium, sodium, and magnesium, as well as the calcium and succinate salts of citrate, phosphate, lactate and gluconate.

15 The present formulations may also contain a tablet lubricant. The lubricant will be present in the formulation at a concentration in the range of about 0.5% to about 4.0% by weight, preferably from about 1.0% to about 2.5% by weight. Preferred lubricants are stearic acid, in powder form, and magnesium stearate. Other suitable tablet lubricants are calcium or zinc stearate, hydrogenated vegetable oils, talc, polyethylene glycols, mineral oil or other pharmaceutically acceptable die wall lubricants.

20 If desired, other conventional tablet ingredients such as preservatives, stabilizers, glidants, pharmaceutically acceptable surface active agents, and FD&C colors may be included in the present formulations. The 25 total weight of these ingredients is typically in the range of about 0.1% to about 2.0% of the weight of the formulation. Acceptable glidants or flow enhancers include colloidal silicon dioxide and talc. Acceptable surface active agents include sodium lauryl sulfate, dioctyl sodium sulfosuccinate (DSS), triethanolamine, polyoxyethylene sorbitan and poloxalkol derivatives, quaternary ammonium salts or other pharmaceutically acceptable surface active agents. Additionally, the lubricants and surface active agents can be combined 30 and incorporated in the formulation as a single ingredient.

35 The resulting tablets may be coated, if desired, with one of many readily available coating systems. Coating the tablets serves to mask the taste of the drug, make the tablet easier to swallow and, in some cases, improve the appearance of the dosage form. The tablets can be sugar coated according to procedures well known in the art, or can be coated with any one of numerous polymeric film coating agents 40 frequently employed by formulation chemists. Representative examples of such film coating agents include hydroxypropyl methylcellulose, carboxymethylcellulose, hydroxypropyl cellulose, methylcellulose, ethylcellulose, acrylic resins, povidone, polyvinyl diethylaminoacetate, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, acrylic latex emulsions, ethylcellulose latex emulsions or other commercially available preparations such as Pharmacoat, manufactured by Shin-Etsu Chemical Co., Ltd, and Opadry, manufactured by Colorcon, Inc.

45 The present formulations may be prepared by procedures well known to formulation chemists. The method of manufacturing can affect the release characteristics of the finished tablets. The acrylic polymer employed in the present formulations may be incorporated into the formulation in a number of ways. The polymer may be added as a finely divided powder to the active agent along with all or part of the hydrophilic polymer. These ingredients are thoroughly mixed and granulated with either water or an aqueous solution of the hydrophilic polymer or other binder. This granulation is dried and sized. The resulting granulation may be blended with additional hydrophilic polymer and tablet lubricants, and then compressed into tablets. This particular method of manufacture requires a larger percentage of enteric 50 polymer to yield the desired balance of appropriate release in both simulated gastric fluids and simulated intestinal fluids, but eliminates the need for organic solvents during the manufacture of the tablets.

55 Alternatively, the acrylic polymer can be added as a finely divided powder to the active agent and optionally all or part of the hydrophilic polymer. These ingredients are thoroughly mixed. Next, rather than using aqueous ingredients during the granulation step, organic solvents such as isopropyl alcohol, ethanol and the like may be employed with or without water. If desired, a suitable hydrophilic polymer can be dissolved in the solvent. Using this type of granulating fluid, the finely divided enteric polymer may become activated or partially dissolved during the granulation phase. In this state, it may be more effective in retarding drug release at low pH. This granulation is then processed as described above. This method of incorporation may result in reduced requirements for both the enteric polymer and hydrophilic polymer, which may be a significant advantage when the active agent is very soluble or is to be employed at high doses.

56 A minor variation of the above method would be to dissolve the acrylic polymer in an appropriate solvent system such as isopropyl alcohol, ethanol, and the like, with or without water. The resulting solution of the acrylic polymer is then used to granulate the active agent which may optionally contain a portion of

the hydrophilic polymer. This method of incorporation allows the acrylic polymer to more effectively retard drug release at low pH. The resulting granulation is then processed as described above. This processing method may again result in reduced requirements for both the acrylic polymer and hydrophilic polymer.

A third method for incorporation of the acrylic polymer into a composition of the invention requires using an aqueous latex dispersion of the polymer as the granulating fluid. In this instance, the active agent and all or part of the hydrophilic polymer would be thoroughly mixed. The dispersion of the acrylic polymer is then added to complete the granulation. The resulting tablets have many of the properties of the solvent granulation tablets described above, but this method does not require the use of these solvents. The aqueous dispersion, however, may not possess much tackiness, and the hydrophilic polymer which may be required to yield a suitable granulation by this method, may yield tablets which do not have the desired release profile at high and low pH that can be achieved using other manufacturing procedures.

The method of incorporation of the hydrophilic polymer will also have an effect on the release rate of the resulting tablets. These effects are well known to those familiar with hydrogel technology. It should be noted that when higher viscosity hydrophilic polymers are added to the formulation prior to wet granulation with aqueous solutions, the resulting tablets may have compromised release profiles when exposed to media of pH high enough to dissolve the enteric polymer.

As noted above, examples of agents for which this invention is particularly suited are cephalexin and cefaclor. When these compounds were placed into a conventional hydrogel composition, the release rate was faster in simulated gastric fluids than when the formulation was exposed to simulated intestinal fluids.

This characteristic is demonstrated by the following example:

Example A

The following example is a cephalexin monohydrate sustained release tablet prepared using conventional hydrogel technology:

	<u>Per Tablet Unit Formula</u>	<u>weight (mg)</u>
30	cephalexin	1074.5 mg
	povidone-90	24.0 mg
	Methocel E4M Premium	161.3 mg
35	stearic acid powder	15.1 mg
	magnesium stearate	15.1 mg

The release tendencies of these tablets were evaluated using two dissolution procedures. One procedure is termed the "gastric method" and the other procedure is the "simulated GI method". According to the gastric method, the tablets were evaluated in 0.1 N hydrochloric acid which represents simulated gastric fluids. The simulated gastrointestinal (GI) method was designed to simulate gastrointestinal transit. According to the simulated GI method, the tablets were exposed for one hour to 750 ml of 0.1 N hydrochloric acid, at which time the pH in the dissolution kettle was increased to pH 6.8 by the addition of 250 ml of 0.2 M tribasic sodium phosphate. The dissolution results of these tablets are presented below:

Cephalexin Dissolved (Cumulative Percent)

Time (minutes)	Gastric Method	Simulated GI Method
5	30	17
10	60	28
15	90	33
20	120	48
25	180	65
30	240	79
35	300	90
40	360	98
45	420	105

The tablets were placed into a 2.00mm [10 mesh] basket and were rotated in the above media at 100 rpm.

The dissolution data illustrates a potential problem with the use of conventional hydrogel technology with a compound whose solubility declines as the pH is increased. With the above formulation, when the tablets were exposed to media of a higher pH in the simulated GI method, the release rate of cephalexin from the formulation declined dramatically. When used clinically, this formulation may not perform as intended if the dosage form does not remain in the stomach. Premature emptying of the tablet into the small intestine, and the resulting pH increase, could result in a decreased cephalexin release rate and poor bioavailability. These conditions would lead to potential problems if they occurred on a continued basis, such as therapeutic failure in the treatment of some types of infection.

The following Examples illustrate the formulations of the invention, and methods of for their preparation.

Example 1

A Hobart mixer was charged with 2149 g of cephalexin monohydrate. The resulting mixture was granulated with 1000 ml of 15% w/v Eudragit L-100-55 in a mixture of isopropyl alcohol:water (9:1, v:v). Total granulating time was between five to seven minutes. The wet granulation was placed through a 4.75 mm [No. 4] screen onto paper-lined trays and dried at 35°C for five and one-half hours. Drying was continued at room temperature overnight. The dried granulation was placed through a 1.40 mm [No. 14 mesh] screen into an appropriate container.

A v-blender was charged with 575 g of this granulation and 62.5 g of hydroxypropyl methylcellulose E-50 to prepare 500 tablets. This mixture was blended for about thirty minutes. To the mixture was added stearic acid powder (7.5 g) and magnesium stearate (3.25 g) through a 600 µm [No. 30 mesh] screen. This material was mixed for five minutes and discharged into an appropriate container. The resulting mixture was compressed on a Stokes F-press tabletting machine using conventional tooling.

45

50

55

Per Tablet Unit Formula:

		weight (mg)	weight (percent)
5			
	cephalexin monohydrate	1074.5	82.91
	Eudragit L-100-55	75.0	5.79
10	hydroxypropyl methylcellulose E-50	125.0	9.65
	stearic acid powder	15.0	1.15
	magnesium stearate	6.5	0.50

15 The dissolution of these tablets was evaluated by the previously described methods with the following results:

	<u>Cephalexin Dissolved (Cumulative Percent)</u>		
	<u>Time (minutes)</u>	<u>Gastric Method</u>	<u>Simulated GI Method</u>
25	30	22	20
	60	35	32
	90	45	40
30	120	53	50
	180	66	69
	240	77	84
35	300	85	92
	360	94	93
	420	100	93

40 Example 2

A Hobart mixer was charged with 1612 g of cephalexin monohydrate, 300 g of Eudragit L-100-55 and 225 g of hydroxypropyl methylcellulose E-5 through an appropriate screen. The mixture was blended 45 thoroughly and granulated with 750 ml of an 8% w/v hydroxypropyl methylcellulose E-5 solution in a mixture of isopropyl alcohol and water (3:7, v:v). Total granulating time was between five and ten minutes. The wet granulation was placed through a 4.75 mm [No. 4] screen onto paper-lined trays and dried at 45°C for one half hour. Drying continued at room temperature for 48 hours. The dried granulation was placed through a 1.40 mm [No. 14 mesh] screen into an appropriate container.

50 A v-blender was charged with 732 g of this granulation followed by 11 g of stearic acid powder and 7.77 g of magnesium stearate were added through a 600 µm [No. 30 mesh] screen. This material was mixed for five minutes and discharged into an appropriate container. The resulting mixture was compressed on a Stokes F-press tabletting machine using conventional tooling.

55 The resulting tablets were film coated with a solvent based film coating mixture consisting of hydroxypropyl methylcellulose E-50 (1.581 weight percent) and glycerin (0.552 weight percent) in a conventional coating pan. The tablets were then placed onto paper-lined trays to dry to provide approximately 1000 tablets.

Per Tablet Unit Formula:		weight (mg)	weight (percent)
5	cephalexin monohydrate	537.23	71.54
	Eudragit L-100-55	100.00	13.32
10	hydroxypropyl methylcellulose E-5	95.00	12.65
	stearic acid powder	11.00	1.46
	magnesium stearate	7.77	1.03
	clear film coat (theory)	15.88	

15 The dissolution of these tablets was evaluated by the previously described methods with the following results:

20 Cephalexin Dissolved (Cumulative Percent)

	Time (minutes)	Gastric Method	Simulated GI Method
25	30	28	27
	60	48	46
	90	65	60
30	120	82	73
	180	100	93
	240	100	99

35 Example 3

A pony mixer was charged with 3224 g of cephalexin monohydrate, 300 g of Eudragit L-100-55 and 93 g of hydroxypropyl cellulose L.F. through an appropriate screen. The mixture was blended thoroughly and 40 granulated with 1200 ml of a 6% w/v aqueous hydroxypropyl cellulose L.F. solution. Purified water was added in a quantity sufficient to produce a satisfactory granulation. Total granulating time was between five and ten minutes. The wet granulation was placed through a 4.75 mm [No. 4] screen onto paper-lined trays and dried at 35°C for 20 1/2 hours. The dried granulation was placed through a 1.70 mm [No. 12 mesh] screen into an appropriate container.

45 To prepare 1000 tablets, a v-blender was charged with 1230 g of this granulation, and 100 g Methocel E4M CR grade was added through a 600 µm [No. 30 mesh] screen. This mixture was blended for about 20 minutes, after which 15 g stearic acid powder and 10.5 g magnesium stearate were added through a 600 µm [No. 30 mesh] screen. This material was mixed for five minutes and discharged into an appropriate container. The resulting mixture was compressed on a Stokes F-press tabletting machine using conventional tooling.

50 The resulting tablets were film coated with a solvent based film coating mixture consisting of hydroxypropyl methylcellulose E-50 (1.581 weight percent) and glycerin (0.552 weight percent) in a conventional coating pan. The tablets were placed onto paper-lined trays to dry.

	Per Tablet Unit Formula:	weight (mg)	weight (percent)
5	cephalexin monohydrate	1074.50	79.30
	Eudragit L-100-55	100.00	7.38
10	hydroxypropyl cellulose L.F.	55.00	4.06
	Methocel E4M CR grade	100.00	7.38
	stearic acid powder	15.00	1.11
	magnesium stearate	10.50	0.77
15	clear film coat (theory)	50.54	

The dissolution of these tablets was evaluated by the previously described methods to provide the
20 following results:

<u>Cephalexin Dissolved (Cumulative Percent)</u>			
	Time (minutes)	Gastric Method	Simulated GI Method
25	30	12	12
	60	31	30
30	90	47	37
	120	60	41
	180	80	58
35	240	93	72
	300	99	82
	360	103	89
40	420	105	93

Example 4

45 A Hobart mixer was charged with 1612 g of cephalexin monohydrate and 45 g of hydroxypropyl cellulose L.F. through an appropriate screen. This mixture was blended thoroughly and granulated with 500 ml of an aqueous dispersion Eudragit L30D (equivalent to 150 g Eudragit L-100-55). Purified water was added in a quantity sufficient to produce a satisfactory granulation. Total granulating time was between five and ten minutes. The wet granulation was placed through a 4.75 mm [No. 4] screen onto paper-lined trays and dried at 35°C for 20 hours. The dried granulation was placed through a 1.40 mm [No. 14 mesh] screen into an appropriate container.

To prepare 500 tablets, a v-blender was charged with 602 g of this granulation and 50 g of Methocel E4M CR grade was added through a 600 µm [No. 30 mesh] screen. This mixture was blended for about 20 minutes, after which 7.5 g of stearic acid powder and 5.25 g magnesium stearate were added through a No. 56 30 mesh screen. This material was mixed for five minutes and discharged into an appropriate container. The resulting mixture was compressed on a Stokes F-press tabletting machine using conventional tooling.

Per Tablet Unit Formula:	weight (mg)	weight (percent)
cephalexin monohydrate	1074.50	80.79
Eudragit L30D (solids)	100.00	7.52
hydroxypropyl cellulose L.F.	30.00	2.26
Methocel E4M CR grade	100.00	7.52
stearic acid powder	15.00	1.13
magnesium stearate	10.50	0.78

15 The dissolution of these tablets was evaluated by the previously described methods to give the following results:

<u>Cephalexin Dissolved (Cumulative Percent)</u>		
Time (minutes)	Gastric Method	Simulated GI Method
30	22	21
60	33	32
90	42	37
120	50	39
180	63	49
240	75	67
300	85	79
360	93	85
420	97	88

40 Example 5

A Hobart mixer was charged with 2149 g of cephalexin monohydrate. This material was granulated with 1000 ml of a 10% w/v Eudragit L-100-55 in a mixture of isopropyl alcohol and water (9:1, v:v). Total granulating time was about seven minutes. The wet granulation was placed through a 4.75 mm [No. 4] screen onto paper-lined trays and dried at 35°C for two hours. Drying was continued at room temperature overnight. The dried granulation was placed through a 1.40 mm [No. 14 mesh] screen into an appropriate container.

To prepare 300 tablets, a v-blender was charged with 337 g of the granulation and 45 g of hydroxypropyl methylcellulose E-50. This mixture was blended for about thirty minutes. Stearic acid powder (4.5 g) and magnesium stearate (1.95 g) were added to the mixture through a 600 µm [No. 30 mesh] screen. This material was mixed for five minutes and discharged into an appropriate container. The resulting mixture was compressed on a Stokes F-press tabletting machine using conventional tooling.

Per Tablet Unit Formula:

		weight (mg)	weight (percent)
5	cephalexin monohydrate	1074.5	82.91
Eudragit L-100-55		50.0	3.86
10	hydroxypropyl methylcellulose E-50	150.0	11.57
stearic acid powder		15.0	1.16
magnesium stearate		6.5	0.50

15 The dissolution of these tablets was evaluated by the previously described methods with the following results:

Cephalexin Dissolved (Cumulative Percent)

Time (minutes)	Gastric Method	Simulated GI Method
25	30	24
60	38	37
90	47	46
120	54	55
30	180	76
240	94	89
300	99	94

Example 6

40 A Hobart mixer was charged with 500 g of cefaclor monohydrate, 65 g of lactose and 100 g of hydroxypropyl methylcellulose E-5 through an appropriate screen. The mixture was blended thoroughly and granulated with 350 ml of a 5% w/v Eudragit L-100-55 solution in a mixture of isopropyl alcohol and water (19:1, v:v). Total granulating time was between five and ten minutes. The wet granulation was placed through a 4.75 mm [No. 4] screen onto paper-lined trays and dried at 50°C for one hour. Drying continued at room temperature for 48 hours. The dried granulation was passed through a 1.18 mm [No. 16 mesh] screen into an appropriate container.

45 To prepare 500 tablets, a v-blender was charged with 268 g of the granulation, and 3.75 g of stearic acid powder and 2.5 g of magnesium stearate were added through a 600 µm [No. 30 mesh] screen. The resulting mixture was mixed for five minutes and discharged into an appropriate container. The resulting mixture was compressed on a Stokes F-press tabletting machine using conventional tooling.

50

55

Per Tablet Unit Formula:		weight (mg)	weight (percent)
5	cefaclor monohydrate	392.30	71.60
	lactose	50.98	9.30
	Eudragit L-100-55	13.71	2.50
10	hydroxypropyl methylcellulose E-5	78.45	14.32
	stearic acid powder	7.50	1.37
	magnesium stearate	5.00	0.91

15 The dissolution of these tablets was evaluated by the previously described methods with the following results:

20 Cefaclor Dissolved (Cumulative Percent)

	Time (minutes)	Gastric Method	Simulated GI Method
25	30	22	23
	60	33	32
	90	41	54
30	120	47	97
	180	61	112
	240	75	
	300	85	
35	360	92	
	420	97	

40 Example 7

A Hobart mixer was charged with 500 g of cefaclor monohydrate, 40 g of Eudragit L-100-55, 50 g of lactose and 75 g of Pullulan PI-20 through an appropriate screen. The mixture was blended thoroughly and 45 granulated with 200 ml of a 5% w/v hydroxypropyl cellulose L.F. solution in a mixture of isopropyl alcohol and water (19:1, v:v). Total granulating time was between five and ten minutes. The wet granulation was placed through a 4.75mm [No. 4] screen onto paper-lined trays and then dried at 50°C for two hours. Drying continued at room temperature for 24 hours. The dried granulation was placed through a 1.40 mm [No. 14 mesh] screen into an appropriate container.

50 A v-blender was charged with 266 g of the granulation, and 3.75 g stearic acid powder and 2.5 g of magnesium stearate were added to the blender through a 600 µm [No. 30 mesh] screen. This material was mixed for five minutes and discharged into an appropriate container. The resulting mixture was compressed on a Stokes F-press tabletting machine using conventional tooling to provide 500 tablets.

	Per Tablet Unit Formula:	weight (mg)	weight (percent)
5	cefaclor monohydrate	392.30	73.43
	lactose	39.23	7.34
	Eudragit L-100-55	31.36	5.87
10	Pullulan PI-20	58.85	11.02
	stearic acid powder	7.50	1.40
	magnesium stearate	5.00	0.94

15 The dissolution of these tablets was evaluated by the previously described methods to afford the following results:

20 Cefaclor Dissolved (Cumulative Percent)

	<u>Time (minutes)</u>	<u>Gastric Method</u>
25	30	18
	60	24
	90	30
	120	34
30	180	44
	240	50
	300	56
35	360	61
	420	66

40 Example 8

A Hobart mixer was charged with 1177 g of cefaclor monohydrate, 212 g of mannitol and 176 g of hydroxypropyl methylcellulose E-5 through an appropriate screen. The mixture was blended thoroughly and 45 granulated with 720 ml of a 5% w/v Eudragit L-100-55 solution in a mixture of isopropyl alcohol and water (9:1, v:v). Total granulating time was five minutes. The wet granulation was placed through a 4.75 mm [No. 4] screen onto paper-lined trays and dried at 40°C for three hours. Drying continued at room temperature overnight. The dried granulation was placed through a 1.18 mm [No. 16 mesh] screen into an appropriate container.

50 To prepare 1500 tablets, a v-blender was charged with 800 g of this granulation. Stearic acid powder (11.25 g) and magnesium stearate (7.5 g) were added to the blender through a 600 µm [No. 30 mesh] screen. The resulting material was mixed for five minutes and discharged into an appropriate container. The resulting mixture was compressed on a Stokes F-press tabletting machine using conventional tooling.

Per Tablet Unit Formula:

		<u>mg/tablet</u>	<u>%w/w</u>
5	cefaclor monohydrate	392.30	71.83
	mannitol	70.70	12.95
	hydroxypropyl methylcellulose E-5	58.50	10.71
10	Eudragit L-100-55	12.00	2.20
	stearic acid powder	7.50	1.37
	magnesium stearate	5.00	0.94

15 The dissolution of these tablets was evaluated by the previously described methods with the following results:

	<u>Cefaclor Dissolved (Cumulative Percent)</u>		
	<u>Time (minutes)</u>	<u>Gastric Method</u>	<u>Simulated GI Method</u>
25	30	20	21
	60	31	30
	90	38	61
	120	46	111
30	180	63	
	240	79	
	300	91	
35	360	98	
	420	103	

40 Example 9

A Hobart mixer was charged with 1177 g of cefaclor monohydrate, 212 g of mannitol and 176 g of hydroxypropyl methylcellulose E-5 through an appropriate screen. The mixture was blended thoroughly and then granulated with 720 ml of a 5% w/v Eudragit L-100-55 solution in a mixture of isopropyl alcohol and water (9:1, v:v). Total granulating time was about five minutes. The wet granulation was placed through a 4.75 mm [No. 4] screen onto paper-lined trays and dried at 40 °C for three hours. Drying continued at room temperature overnight. The dried granulation was placed through a 1.18 mm [No. 16 mesh] screen into an appropriate container.

To prepare 1100 tablets, a v-blender was charged with 587 g of this granulation and 26.4 g of mannitol. 50 This mixture was blended for about thirty minutes and combined with stearic acid powder (8.25 g) and magnesium stearate (5.5 g) through a 600 µm [No. 30 mesh] screen. This material was mixed for five minutes and discharged into an appropriate container. The resulting mixture was compressed on a Stokes F-press tabletting machine using conventional tooling. The resulting tablets were film coated with a solvent based film coating mixture consisting of hydroxypropyl methylcellulose E-50 (1.55 weight percent), glycerin (0.54 weight percent) and Opaspray Blue (solids - 0.75 weight percent) in a conventional coating pan. The tablets were then placed onto paper-lined trays to dry.

Per Tablet Unit Formula:

		weight (mg)	weight (percent)
5	cefaclor monohydrate	392.30	68.82
	mannitol	94.70	16.61
10	hydroxypropyl methylcellulose E-5	58.50	10.26
	Eudragit L-100-55	12.00	2.11
	stearic acid powder	7.50	1.32
	magnesium stearate	5.00	0.88
15	color film coating (theory)	13.01	

The dissolution of these tablets was evaluated by the previously described methods with the following results:

20

Cefaclor Dissolved (Cumulative Percent)

25	Time (minutes)	Gastric Method	Simulated GI Method
	30	18	18
	60	28	28
30	90	36	53
	120	46	95
	180	66	
35	240	83	
	300	93	
	360	97	

40

Example 10

A Hobart mixer was charged with 1569 g of cefaclor monohydrate, 201 g of mannitol and 264 g of hydroxypropyl methylcellulose E-5 through an appropriate screen. The mixture was blended thoroughly and granulated with 960 ml of a 5% w/v Eudragit L-100-55 solution in a mixture of isopropyl alcohol and water (9:1, v:v). Total granulating time was about six minutes. The wet granulation was placed through a 4.75 mm [No. 4] screen onto paper-lined trays and dried at 28°C for six hours. Drying continued at room temperature overnight. The dried granulation was passed through a 1.18 mm [No. 16 mesh] screen into an appropriate container.

To prepare 1500 tablets, a v-blender was charged with 781 g of the granulation, 11.25 g of stearic acid powder and 7.5 g of magnesium stearate. The lubricants were added through a 600 µm [No. 30 mesh] screen. This material was mixed for five minutes and discharged into an appropriate container. The resulting mixture was then compressed on a Stokes F-press tabletting machine using conventional tooling. The resulting tablets were film coated with a solvent based film coating mixture consisting of hydroxypropyl methylcellulose E-50 (1.55 weight percent), glycerin (0.54 weight percent) and Opaspray Blue (solids - 0.75 weight percent) in a conventional coating pan. The tablets were then placed onto paper-lined trays to dry.

Per Tablet Unit Formula:

		weight (mg)	weight (percent)
5	cefaclor monohydrate	392.30	73.60
	mannitol	50.20	9.42
10	hydroxypropyl methylcellulose E-5	66.00	12.38
	Eudragit L-100-55	12.00	2.25
	stearic acid powder	7.50	1.41
15	magnesium stearate	5.00	0.94
	color film coating (theory)	12.87	

The dissolution of these tablets was evaluated by the previously described methods with the following results:

<u>Cefaclor Dissolved (Cumulative Percent)</u>			
	Time (minutes)	Gastric Method	Simulated GI Method
25	30	17	17
	60	26	26
	90	33	45
30	120	38	82
	180	49	
	240	58	
35	300	67	
	360	76	
	420	83	

40

Example 11

A Hobart mixer was charged with 1046 g of cefaclor monohydrate, 80 g of mannitol and 70 g of hydroxypropyl methylcellulose E-5 through an appropriate screen. The mixture was blended thoroughly and then granulated with 500 ml of a 3% w/v Eudragit L-100-55 and 2.6% w/v hydroxypropyl cellulose EF solution in a mixture of isopropyl alcohol and water (isopropyl alcohol 90 parts : 10 parts water). Total granulating time was between three and four minutes. The wet granulation was placed through a 4.75 mm [No. 4] screen onto paper-lined trays and then dried at 40° C for five hours. Drying continued at room temperature for 24 hours. The dried granulation was placed through a 1.18 µm [No. 16 mesh] screen and the granulation was returned to paper-lined trays and dried at 40° C for 2 1/2 hours to remove residual solvent.

To prepare 900 tablets, a v-blender was charged with 550.8 g of this granulation. To this, 61.2 g of hydroxypropyl methylcellulose E-50 was added through a 600 µm [No. 30 mesh] screen. The mixture was blended for twenty minutes in a v-blender. To this mixture, the lubricants stearic acid powder (6.3 g) and magnesium stearate (2.7 g) were added through a 600 µm [No. 30 mesh] screen. This material was mixed for five minutes and discharged into an appropriate container. The resulting mixture was then compressed on a Stokes F-press tabletting machine using conventional tooling.

The tablets were film coated with a solvent based film coating mixture consisting of hydroxypropyl methylcellulose E-50 (1.581 weight percent), glycerin 0.552 (weight percent) and Opaspray Blue (1.961 weight percent) in a conventional coating pan. The tablets were placed onto paper-lined trays to air dry.

5 **Per Tablet Unit Formula:**

		<u>weight</u> (<u>mg</u>)	<u>weight</u> (<u>percent</u>)
10	cefaclor monohydrate	523.00	75.80
	mannitol	40.20	5.80
	hydroxypropyl methylcellulose E-5	35.00	5.07
15	Eudragit L-100-55	7.50	1.09
	hydroxypropyl cellulose EF	6.50	0.94
	hydroxypropyl methylcellulose E-50	68.00	9.86
20	stearic acid powder	7.00	1.01
	magnesium stearate	3.00	0.43
	blue film coating (theory)	12.50	

25 The dissolution of these tablets was evaluated by the previously described methods with the following results:

<u>Cefaclor Dissolved (Cumulative Percent)</u>			
	<u>Time</u> (<u>minutes</u>)	<u>Gastric Method</u>	<u>Simulated GI Method</u>
	30	16	17
35	60	30	34
	90	44	56
	120	57	71
40	180	81	88
	240	101	100

45 Example 12

To prepare 40 tablets, the following ingredients were passed through a 600 μm [No. 30 mesh] screen and mixed together in a mortar and pestle- 8.44 g of 7-[D-(aminophenylacetyl)amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate, 0.84 g of Eudragit L-100-55, and 2.56 g of hydroxypropyl methylcellulose E-50. To this mixture, 0.104 g of magnesium stearate and 0.216 g of talc were added and blended thoroughly. The resulting mixture was then compressed on a Stokes F-press tabletting machine using conventional tooling.

Per Tablet Unit Formula:

		<u>weight</u> <u>(mg)</u>	<u>weight</u> <u>(percent)</u>
5	7-[D-(aminophenylacetyl)amino]-		
10	3-chloro-8-oxo-1-azabicyclo-[4.2.0]oct-2-ene-2-carboxylic acid monohydrate	211.00	69.41
15	Eudragit L-100-55	21.00	6.91
20	hydroxypropyl methylcellulose E-50	64.00	21.05
	magnesium stearate	2.60	0.86
	talc	5.40	1.78

20 The dissolution of these tablets was evaluated by the previously described methods with the following results:

25	<u>Active Agent Dissolved (Cumulative Percent)</u>		
	<u>Time</u> <u>(minutes)</u>	<u>Gastric Method</u>	<u>Simulated GI Method</u>
30	30	23	24
	60	43	44
	90	65	59
	120	80	68
35	150	92	79
	180	100	87
	240	105	99
40	300	104	105

Example 13

45 To prepare 40 tablets, the following ingredients were passed through a 600 μm [No. 30 mesh] screen and mixed together in a mortar and pestle- 8.0 g of 7-[amino[3-[(methylsulfonyl)amino]phenyl]acetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 0.8 g of Eudragit L-100-55, 1.6 g of hydroxypropyl methylcellulose E-50, and 0.96 g of Methocel E4M CR grade. To this mixture, 0.120 g of magnesium stearate and 0.200 g of talc were added and blended thoroughly. The resulting mixture was then compressed on a Stokes F-press tabletting machine using conventional tooling.

Per Tablet Unit Formula:

		weight (mg)	weight (percent)
5	7-[(amino[3-[(methylsulfonyl)-		
10	amino]phenyl]acetyl]amino]-3-		
15	chloro-8-oxo-1-azabicyclo[4.2.0]-		
20	oct-2-ene-2-carboxylic acid	200.00	68.49
25	Eudragit L-100-55	20.00	6.85
30	hydroxypropyl Methylcellulose E-50	40.00	13.70
35	Methocel E4M CR grade	24.00	8.22
40	magnesium stearate	3.00	1.03
45	talc	5.00	1.71

The dissolution of these tablets was evaluated by the previously described methods with the following results:

	<u>Active Agent Dissolved (Cumulative Percent)</u>		
	<u>Time (minutes)</u>	<u>Gastric Method</u>	<u>Simulated GI Method</u>
30	30	19	18
	60	29	28
	90	40	36
35	120	50	40
	150	58	43
	180	65	48
40	240	78	58
	300	89	69
	360	97	78
	420	100	84

Example 14

50 To prepare 40 tablets, the following ingredients were passed through a 600 μm [No. 30 mesh] screen and mixed together in a mortar and pestle- 8.0 g of 7-[D-amino[3-[(ethyl-sulfonyl)amino]phenyl]acetyl]-amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 0.8 g of Eudragit L-100-55, 1.6 g of hydroxypropyl methylcellulose E-50, and 1.0 g of Methocel E4M CR grade. To this mixture, 0.20 g of magnesium stearate and 0.200 g of talc were added and blended thoroughly. The resulting mixture was then compressed on a Stokes F-press tableting machine using conventional tooling.

Per Tablet Unit Formula:

		<u>weight</u> <u>(mg)</u>	<u>weight</u> <u>(percent)</u>
5	7-[D-[amino[3-[(ethylsulfonyl)- amino]phenyl]acetyl]amino]-3-		
10	chloro-8-oxo-1-azabicyclo[4.2.0]- oct-2-ene-2-carboxylic acid	200.00	67.80
15	Eudragit L-100-55	20.00	6.78
20	hydroxypropyl methylcellulose E-50	40.00	13.56
25	Methocel E4M CR grade	25.00	8.47
	magnesium stearate	5.00	1.69
	talc	5.00	1.69

The dissolution of these tablets was evaluated by the previously described methods with the following results:

	<u>Active Agent Dissolved (Cumulative Percent)</u>		
	<u>Time</u> <u>(minutes)</u>	<u>Gastric Method</u>	<u>Simulated GI Method</u>
30	30	18	17
	60	27	28
	90	34	35
35	120	43	39
	150	50	42
	180	56	47
40	240	67	56
	300	76	65
	360	86	75
45	420	92	84

Claims

Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

50 1. A sustained release matrix formulation in tablet form comprising from 0.1% by weight to 90% by weight of an antimicrobial agent selected from cephalexin, cefaclor, cefadroxil, cefuroxime, cefuroxime axetil, erythromycin, penicillin, loracarbef, 7-[[amino-3-[(methylsulfonyl)amino]-phenyl]acetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]-oct-2-ene-2-carboxylic acid, or 7-[D-[amino[3-[(ethylsulfonyl)amino]phenyl]-acetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]-oct-2-ene-2-carboxylic acid, from 5% by weight to 29% by weight of a hydrophilic polymer, and from 0.5% by weight to 25% by weight of an acrylic polymer which dissolves at a pH of 5 to 7.4, with the proviso that the total weight of the hydrophilic polymer and the acrylic polymer is less than 30% by weight of the formulation.

2. A formulation as claimed in Claim 1 in which the antimicrobial agent is cefaclor.
3. A formulation as claimed in Claim 1 in which the antimicrobial agent is cephalexin.
5. 4. A formulation as defined in Claim 1 for use in the therapeutic treatment of a warm-blooded animal in need thereof.

Claims for the following Contracting States : GR, ES

10. 1. A process for preparing a tableted medicament comprising a sustained release matrix containing from 0.1% by weight to 90% by weight of an antimicrobial agent selected from cephalexin, cefaclor, cefadroxil, cefuroxime; cefuroxime axetil, erythromycin, penicillin, loracarbef, 7-[(amino-[3-[(methylsulfonyl)-amino]phenyl]acetyl]amino]-3-chloro-8-oxo-1-azabicyclo-[4.2.0]oct-2-ene-2-carboxylic acid, or 7-[D-[amino[3-[(ethylsulfonyl)amino]phenyl]acetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, from 5% by weight to 29% by weight of a hydrophilic polymer, and from 0.5% by weight to 25% by weight of an acrylic polymer which dissolves at a pH of 5 to 7.4, with the proviso that the total weight of the hydrophilic polymer and the acrylic polymer is less than 30% by weight of the formulation; which comprises granulating a thorough mixture of the antimicrobial agent, the hydrophilic polymer and the acrylic polymer with an aqueous or organic solvent system, drying the granules, charging the dried granules and a tablet lubricant into a blender, discharging the blender and tableting the resulting product.
20. 2. A process of claim 1 in which the solvent system is aqueous.
25. 3. A process of claim 2 in which the solvent system is water.
4. A process of claim 3 in which the water contains all or part of the hydrophilic polymer.
5. A process of claim 3 in which the water contains all or part of the acrylic polymer.
30. 6. A process of claim 1 in which the solvent system is organic.
7. A process of claim 6 in which the organic solvent contains all or part of the hydrophilic polymer.
35. 8. A process of claim 6 in which the organic solvent contains all or part of the acrylic polymer.
9. A process as claimed in any preceding claim in which the antimicrobial agent is cefaclor.
10. A process as claimed in any preceding claim in which the antimicrobial agent is cephalexin.

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

45. 1. Einen Wirkstoff verzögert freigebende Matrixformulierung in Form einer Arzneimitteltablette, enthaltend 0,1 Gewichtsprozent bis 90 Gewichtsprozent eines antimikrobiellen Mittels, ausgewählt aus Cephalexin, Cefaclor, Cefadroxil, Cefuroxim, Cefuroximaxetil, Erythromycin, Penicillin, Loracarbef, 7-[(Amino-[3-[(methylsulfonyl)-amino]phenyl]acetyl]amino)-3-chlor-8-oxo-1-azabicyclo[4.2.0]oct-2-en-2-carbonsäure oder 7-[D-[Amino[3-[(ethylsulfonyl)amino]phenyl]acetyl]amino]-3-chlor-8-oxo-1-azabicyclo[4.2.0]oct-2-en-2-carbonsäure, 5 Gewichtsprozent bis 29 Gewichtsprozent eines hydrophilen Polymers und 0,5 Gewichtsprozent bis 25 Gewichtsprozent eines Acrylpolymer, das sich bei einem pH-Wert von 5 bis 7,4 löst, mit der Maßgabe, daß das Gesamtgewicht aus dem hydrophilen Polymer und dem Acrylpolymer weniger als 30 Gewichtsprozent der Formulierung ausmacht.
55. 2. Formulierung nach Anspruch 1, worin das antimikrobielle Mittel Cefaclor ist.
3. Formulierung nach Anspruch 1, worin das antimikrobielle Mittel Cephalexin ist.

4. Formulierung nach Anspruch 1 zur Anwendung bei der therapeutischen Behandlung eines einer solchen Behandlung bedürfenden Warmblüters.

Patentansprüche für folgende Vertragsstaaten : GR, ES

5. 1. Verfahren zur Herstellung einer eine den Wirkstoff verzögernd freigebende Matrix umfassenden Arzneimitteltablette, enthaltend 0,1 Gewichtsprozent bis 90 Gewichtsprozent eines antimikrobiellen Mittels, ausgewählt aus Cephalexin, Cefaclor, Cefadroxil, Cefuroxim, Cefuroximaxetil, Erythromycin, Penicillin, Loracarbef, 7-[[Amino-3-[(methylsulfonyl)amino]phenyl]acetyl]amino]-3-chlor-8-oxo-1-azabicyclo[4.2.0]oct-2-en-2-carbonsäure oder 7-[D-[Amino-3-[(ethylsulfonyl)amino]phenyl]acetyl]amino]-3-chlor-8-oxo-1-azabicyclo[4.2.0]oct-2-en-2-carbonsäure, 5 Gewichtsprozent bis 29 Gewichtsprozent eines hydrophilen Polymers und 0,5 Gewichtsprozent bis 25 Gewichtsprozent eines Acrylpolymer, das sich bei einem pH-Wert von 5 bis 7,4 löst, mit der Maßgabe, daß das Gesamtgewicht aus dem hydrophilen Polymer und dem Acrylpolymer weniger als 30 Gewichtsprozent der Formulierung ausmacht, dadurch gekennzeichnet, man ein gründliches Gemisch aus dem antimikrobiellen Mittel, dem hydrophilen Polymer und dem Acrylpolymer mit einem wässrigen oder organischen Lösemittelsystem granuliert, die Granulat trocknet, die getrockneten Granulat und ein Gleitmittel für Tabletten in einen Mischer gibt, den Mischer entleert und das erhaltene Produkt tabletliert.

10. 2. Verfahren nach Anspruch 1, worin das Lösemittelsystem ein wässriges Lösemittelsystem ist.

3. Verfahren nach Anspruch 2, worin das Lösemittelsystem Wasser ist.

4. Verfahren nach Anspruch 3, worin das Wasser das gesamte hydrophile Polymer oder ein Teil hiervon enthält.

15. 5. Verfahren nach Anspruch 3, worin das Wasser das gesamte Acrylpolymer oder ein Teil hiervon enthält.

6. Verfahren nach Anspruch 1, worin das Lösemittelsystem ein organisches Lösemittelsystem ist.

20. 7. Verfahren nach Anspruch 6, worin das organische Lösemittel das gesamte hydrophile Polymer oder einen Teil hiervon enthält.

8. Verfahren nach Anspruch 6, worin das organische Lösemittel das gesamte Acrylpolymer oder einen Teil hiervon enthält.

25. 9. Verfahren nach einem der vorhergehenden Ansprüche, worin das antimikrobielle Mittel Cefaclor ist.

10. Verfahren nach einem der vorhergehenden Ansprüche, worin das antimikrobielle Mittel Cephalexin ist.

40. **Revendications**

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

45. 1. Formulation de matrice à relargage soutenu en orme de cachet comprenant de 0,1% en poids à 90% en poids d'un agent antimicrobien sélectionné parmi céphalexine, céfaclor, céfadroxile, céfuroxime, céfuroxime axétile, érythromycine, pénicilline, loracarbef, acide 7-[[amino-3-[(methylsulfonyl)amino]phényl]acétyle]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylique, ou 7-[D-[amino-3-[(ethylsulfonyl)amino]phényle]acétyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ène-2-acide carboxylique, de 5% en poids à 29% en poids d'un polymère hydrophile et de 0,5% en poids à 25% en poids d'un polymère acrylique qui se dissout à un pH de 5 à 7,4, avec la condition que le poids total du polymère hydrophile et du polymère acrylique constitue moins de 30% en poids de la formulation.

50. 2. Formulation telle que revendiquée dans la revendication 1 dans laquelle l'agent antimicrobien est la céfaclor.

55. 3. Formulation telle que revendiquée dans la revendication 1 dans laquelle l'agent antimicrobien est la céphalexine.

4. Formulation telle que revendiquée dans la revendication 1 pour l'utilisation dans le traitement thérapeutique d'animaux à sang chaud qui ont besoin d'un tel traitement.

Revendications pour les Etats contractants suivants : GR, ES

5 1. Procédé pour la préparation d'un médicament sous forme de cachet contenant une matrice à relargage soutenu contenant de 0,1% en poids à 90% en poids d'un agent antimicrobien sélectionné parmi céphalexine, céfaclor, céfadroxile, céfuroxime, céfuroxime axétile, érythromycine, pénicilline, loracarbef, acide 7-[[amino-[3-[(méthylsulfonyl)amino]-phényl]acétyle]amino]-3-chloro-8-oxo-1-azabicyclo-[4.2.0]-oct-2-ène-2-carboxylique, ou 7-[D-[amino[3-[(éthylsulfonyl)amino]phényl]acétyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylique, de 5% en poids à 29% en poids d'un polymère hydrophile et de 0,5% en poids à 25% en poids d'un polymère acrylique qui se dissout à un pH de 5 à 7,4, avec la condition que le poids total du polymère hydrophile et du polymère acrylique constitue moins de 30% en poids de la formulation, qui comprend la granulation d'un mélange infime de l'agent antimicrobien, du polymère hydrophile et du polymère acrylique avec un système de solvants aqueux ou organiques, le séchage des granules, le chargement des granules séchées et d'un lubrifiant pour cachets dans le mélangeur, le déchargeement du mélangeur et la cachétisation du produit résultant.

10 2. Procédé de la revendication 1 dans lequel le système de solvants est aqueux.

15 3. Procédé de la revendication 2 dans lequel le système de solvants est de l'eau.

20 4. Procédé de la revendication 3 dans lequel l'eau contient tout ou une partie du polymère hydrophile.

25 5. Procédé de la revendication 3 dans lequel l'eau contient tout ou une partie du polymère acrylique.

30 6. Procédé de la revendication 1 dans lequel le système de solvants est organique.

35 7. Procédé de la revendication 6 dans lequel le solvant organique contient tout ou une partie du polymère hydrophile.

40 8. Procédé de la revendication 6 dans lequel le solvant organique contient tout ou une partie du polymère acrylique.

35 9. Procédé de l'une quelconque des revendications précédentes dans lequel l'agent antimicrobien est la Céfaclor.

10. Procédé de l'une quelconque des revendications précédentes dans lequel l'agent antimicrobien est la Céfalaxine.

40

45

50

55